Alcohol and risk of liver cancer

Share This Post

Does alcohol increases the risk of liver cancer ? For this question, we got affirmative answers from some experts and professors at the Medical Academic Medical Center of the University of Southern California. Excessive drinking can cause liver cancer, which is a fact that has been established. If diagnosed early, patients have more treatment options, so screening is the key.

So, what are the causes of liver cancer? In most cases, liver cancer is caused by cirrhosis, which is caused by inflammation and scarring of liver cells. There are three main causes of cirrhosis: hepatitis B and hepatitis C viruses; non-alcoholic steatohepatitis (NASH). NASH is caused by fatty liver, and its risk factors include obesity, gastric bypass surgery, high cholesterol and type 2 diabetes. Some NASH patients directly develop liver cancer without cirrhosis. Overweight and alcoholics also face double risks. The third reason is alcoholic liver disease.

Most occasional social drinkers will not contract alcoholic cirrhosis. A reliable way to protect yourself from alcoholic liver disease is to avoid drinking altogether. People who drink a lot of alcohol have a greater risk of liver cancer. Therefore, people who drink too much should be screened for liver cancer. The screening process is simple and non-invasive, and the doctor will perform an ultrasound examination of the liver to detect cysts, obstructions or infections in the liver and to check for cancer. If an abnormality is found on the ultrasound, the doctor will determine if you need additional tests, such as CT scans, MRI, or alpha-fetal protein tests, which can identify the tumor.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS
Cancer

Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS

Lutetium Lu 177 dotatate, a groundbreaking treatment, has recently received approval from the US Food and Drug Administration (FDA) for pediatric patients, marking a significant milestone in pediatric oncology. This approval represents a beacon of hope for children battling neuroendocrine tumors (NETs), a rare but challenging form of cancer that often proves resistant to conventional therapies.

Nogapendekin alfa inbakicept-pmln is approved by the USFDA for BCG-unresponsive non-muscle invasive bladder cancer
Bladder cancer

Nogapendekin alfa inbakicept-pmln is approved by the USFDA for BCG-unresponsive non-muscle invasive bladder cancer

“Nogapendekin Alfa Inbakicept-PMLN, a novel immunotherapy, shows promise in treating bladder cancer when combined with BCG therapy. This innovative approach targets specific cancer markers while leveraging the immune system’s response, enhancing the efficacy of traditional treatments like BCG. Clinical trials reveal encouraging results, indicating improved patient outcomes and potential advancements in bladder cancer management. The synergy between Nogapendekin Alfa Inbakicept-PMLN and BCG heralds a new era in bladder cancer treatment.”

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy